OSAKA (Kyodo) Rohto Pharmaceutical Co. will start producing and selling Chinese drugs in China in December with an annual sales target of hundreds of millions of yen, the company said Tuesday.
The Osaka-based major drugmaker has already set up a joint venture in Tianjin, China, together with Tokyo-based drug firm Uchida Wakanyaku Co. and a Chinese company. Rohto holds 80 percent of the venture, while the other two own 10 percent each.
Rohto considers China its top priority market and aims to boost sales there of Chinese medicines and drug extracts.
In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.